

Lung Cancer Treatment **contro**versies



2026

06-07 NOVEMBER • PORTO



Registrations

Preliminary Program

2026

06-07 NOVEMBER · PORTO



Organizing Committee / Scientific Coordinators

António Araújo

Unidade Local de Saúde Santo António /
School of Medicine and Biomedical Sciences –
ICBAS, University of Porto, Porto, Portugal

Delvys Rodriguez-Abreu

Hospital Universitario Insular, Las Palmas de
Gran Canaria, Spain

Luiz Paz-Ares

Hospital Universitario 12 de Octubre, Madrid, Spain

Stephen Liu

Lombardi Cancer Center Georgetown University,
Washington, USA

Position Paper Coordinator

Ana Rodrigues

Portuguese Institute of Oncology – Porto Center, Porto, Portugal

Scientific Panel

Alfredo Addeo ⁽¹⁾

Alvaro Quintanal-Villalonga ⁽²⁾

Andrea Ardissoni ⁽³⁾

António Araújo ⁽⁴⁾

Benjamin Besse ⁽⁵⁾

Cecilia Pompili ⁽⁶⁾

Christian Rolfo ⁽⁷⁾

Delvys Rodriguez-Abreu ⁽⁸⁾

Enriqueta Felip ⁽⁹⁾

Fiona Blackhall ⁽¹⁰⁾

Joachim Aerts ⁽¹¹⁾

Jessica Lin ⁽¹²⁾

Jon Zugazagoitia ⁽¹³⁾

Jordi Remon ⁽¹⁴⁾

Lizza Hendriks ⁽¹⁵⁾

Luiz Paz-Ares ⁽¹⁶⁾

Rosario Garcia Campelo ⁽¹⁷⁾

Stephen Liu ⁽¹⁸⁾

Suresh Senan ⁽¹⁹⁾



General Information

Venue:

School of Medicine and Biomedical
Sciences – ICBAS, University of Porto
Rua de Jorge de Viterbo Ferreira, 228, 4050-313 Porto

Format and language:

Short lectures and pro-con debates to draw
conclusions from the debate and to vote among
all the audience. Communication in English.

Registrations and Website

www.lungcancertreatmentcontroversies.com

Audience:

Thoracic oncologists, surgeons,
radiation oncologists, translational
researchers.

Technical Secretary:

Skyros Congressos, Lda



Day 1

Friday, 6 November

08:15

› **Registration opening**

08:45–09:00

› **Welcome & Objectives**

Session 1

09:00–13:00

Early Stages: Are We Over or Under-Treating?

Chairs: Delvys Rodriguez-Abreu & Christian Rolfo

Controversies – Pro and Con (10' each talk followed 40' for discussion and conclusions)

■ Perioperative vs neo-adjuvant IO.

Speakers: Lizza Hendriks vs Alfredo Addeo

■ Are we ready for targeted therapy in resected oncogene-driven NSCLC?

Speakers: Jessica Lin vs Rosario Garcia Campelo

10:45–11:15 › Coffee Break

■ Should MRD guide adjuvant therapy in 2026?

Speaker: Christian Rolfo

■ In multiple station N2, bulky N2 or T4 – Neoadjuvant pre-surgery or chemoradiation and IO?

Speakers: Cecilia Pompili vs Suresh Senan

13:00–14:00 › Lunch

Session 2

14:00–18:00

First-line Treatment for advanced NSCLC: what is the size?

Chairs: Stephen Liu & Jessica Lin

Controversies – Pro and Con (10' each talk followed 40' for discussion and conclusions)

■ In PD-L1 ≥ 50% IO alone vs chemo-IO or IO combinations.

Speakers: Stephen Liu vs Enriqueta Felip

■ Sequencing vs combinations in oncogene-driven disease.

Speakers: Delvys Rodriguez-Abreu vs Jessica Lin

15:45–16:15 › Coffee Break

■ What is the best duration of the IO therapy? Two years vs until disease progression.

Speakers: Benjamin Besse vs Joachim Aerts

■ The value of new strategies (like ADCs or bispecific antibodies) vs (and) the need for new biomarkers.

Speaker: Jordi Remon

Day 2

Saturday, 7 November

Session 3

09:00–13:00

mSCLC: is this the future?

Chairs: António Araújo & Luiz Paz-Ares

Controversies – Pro and Con (10' each talk followed 40' for discussion and conclusions)

■ Molecular subtypes and other biomarkers: ready for clinical use?

Speaker: Alvaro Quintanal-Villalonga

■ Maintenance with PD-L1/PD-1 inhibitors or Lurbinectedin+Atezolizumab?

Speakers: Andrea Ardizzoni vs Jon Zugazagoitia

10:45–11:15 › Coffee Break

■ T-Cells Engager – some patients in some centers or most patients in most centers?

Speakers: Fiona Blackhall vs Luiz Paz-Ares

■ After chemo-immunotherapy progression: should we move directly to T-cell engagers or still sequence conventional therapies?

Speakers: Benjamin Besse vs Stephen Liu

13:00–13:30 › Closing Session

■ Take-home messages and consensus gaps

■ Proposal for post-meeting position paper



2026

06-07 NOVEMBER · PORTO



Under the auspices of:



LIGA
PORTUGUESA
CONTRA
O CANCRO
Núcleo Regional do Norte



PULMONALE
ASSOCIAÇÃO PORTUGUESA DE LUTA
CONTRA O CANCRO DO PULMÃO



SOCIEDADE
PORTUGUESA DE
ONCOLOGIA



GECP
GRUPO DE ESTUDOS
DO CANCRO DO PULMÃO



IASLC
INTERNATIONAL
ASSOCIATION
OF LUNG
CANCER
SYMPOSIUM

Support:

PLATINUM



GOLD

SILVER



BRONZE



COLLABORATORS

